Clinical trial
A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
NCT00089479 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00089479 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer |
| Official title | A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine [Xeloda], Taxotere |
| Enrollment | 2,611 |
| Start date | Aug 1, 2002 |
| Primary completion | Jun 1, 2010 |
| Completion | May 1, 2012 |
| First posted | Aug 6, 2004 |
| Last update posted | Dec 21, 2012 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: